Zimmer Biomet Holdings Inc (NYSE:ZBH) has been given a consensus recommendation of “Hold” by the twenty-six ratings firms that are covering the firm, MarketBeat reports. Three research analysts have rated the stock with a sell rating, nine have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $131.24.
A number of analysts recently commented on the stock. Zacks Investment Research cut shares of Zimmer Biomet from a “hold” rating to a “sell” rating in a research note on Saturday, April 13th. Barclays lifted their target price on shares of Zimmer Biomet from $113.00 to $117.00 and gave the stock an “underweight” rating in a research note on Monday, April 15th. Evercore ISI upgraded shares of Zimmer Biomet from an “in-line” rating to an “outperform” rating and set a $145.00 target price for the company in a research note on Monday, April 8th. Morgan Stanley lifted their target price on shares of Zimmer Biomet from $132.00 to $143.00 and gave the stock an “overweight” rating in a research note on Monday, March 4th. Finally, Cantor Fitzgerald set a $135.00 target price on shares of Zimmer Biomet and gave the stock a “buy” rating in a research note on Friday, April 26th.
In other news, insider Sang Yi sold 426 shares of Zimmer Biomet stock in a transaction that occurred on Friday, May 24th. The shares were sold at an average price of $114.88, for a total transaction of $48,938.88. Following the completion of the transaction, the insider now directly owns 1,457 shares of the company’s stock, valued at approximately $167,380.16. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.72% of the stock is owned by insiders.
Several large investors have recently bought and sold shares of ZBH. Vanguard Group Inc grew its stake in Zimmer Biomet by 1.6% in the 3rd quarter. Vanguard Group Inc now owns 14,511,433 shares of the medical equipment provider’s stock valued at $1,907,818,000 after acquiring an additional 228,894 shares during the period. TD Asset Management Inc. grew its stake in Zimmer Biomet by 25.5% in the 4th quarter. TD Asset Management Inc. now owns 72,458 shares of the medical equipment provider’s stock valued at $7,515,000 after acquiring an additional 14,704 shares during the period. Chicago Equity Partners LLC acquired a new stake in Zimmer Biomet in the 4th quarter valued at $557,000. Daiwa Securities Group Inc. grew its stake in Zimmer Biomet by 9.1% in the 4th quarter. Daiwa Securities Group Inc. now owns 8,085 shares of the medical equipment provider’s stock valued at $839,000 after acquiring an additional 672 shares during the period. Finally, Victory Capital Management Inc. grew its stake in Zimmer Biomet by 3.2% in the 4th quarter. Victory Capital Management Inc. now owns 475,264 shares of the medical equipment provider’s stock valued at $49,294,000 after acquiring an additional 14,518 shares during the period. 88.77% of the stock is owned by hedge funds and other institutional investors.
ZBH stock opened at $119.79 on Friday. The company has a market capitalization of $24.67 billion, a P/E ratio of 15.68, a P/E/G ratio of 2.22 and a beta of 1.17. The company has a quick ratio of 0.97, a current ratio of 2.00 and a debt-to-equity ratio of 0.72. Zimmer Biomet has a 52 week low of $96.99 and a 52 week high of $134.55.
Zimmer Biomet (NYSE:ZBH) last released its earnings results on Friday, April 26th. The medical equipment provider reported $1.87 EPS for the quarter, topping analysts’ consensus estimates of $1.86 by $0.01. The company had revenue of $1.98 billion during the quarter, compared to analysts’ expectations of $1.97 billion. Zimmer Biomet had a negative net margin of 3.90% and a positive return on equity of 13.24%. Zimmer Biomet’s revenue for the quarter was down 2.1% on a year-over-year basis. During the same period last year, the business earned $1.91 EPS. As a group, equities research analysts forecast that Zimmer Biomet will post 7.81 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 31st. Stockholders of record on Friday, June 28th will be issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 0.80%. The ex-dividend date of this dividend is Thursday, June 27th. Zimmer Biomet’s dividend payout ratio (DPR) is 12.57%.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.
Read More: What is Put Option Volume?
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.